About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The main characteristic of our group is its multidisciplinary nature, as it is comprised of neuroradiologists, technologists, and a physicist, engineer, and biochemist.
The main objectives of our projects are to gain knowledge about the pathophysiologic mechanisms implicated in several neurological diseases and to evaluate new biomarkers and therapies through the use of qualitative and quantitative magnetic resonance (MR) and computed tomography (CT) techniques, and by applying artificial intelligence tools to create prognostic models. Our focus is on the study of diseases such as multiple sclerosis, epilepsy, neuro-oncology, and stroke.
In addition, because of the experience we have acquired along the years in performing MR studies, we act as a platform for designing MR-based projects, processing images, and conducting quantitative data analysis.
The objective of this research line is to evaluate the value of MRI in the diagnosis of multiple sclerosis and as a marker of progression and treatment response to disease modifying treatments.
IP: Alex Rovira Cañellas, Cristina Auger Acosta
The objective of this research line is to evaluate the value of MRI in the diagnosis and follow-up of primary tumours of central nervous system, with special interest on the impact of radiological features in predicting their genomics characteristics (radiogenomics), through multicentre studies.
IP: Cristina Auger Acosta
The objective of this research line is to evaluate the value of MRI in the diagnosis and follow-up of primary tumours of the head and neck, with special interest on the impact of radiological features in their prognosis.
IP: -
This research line aims to develop new biomarkers that capture brain function and can be implemented in the clinical routine.
IP: Deborah Pareto Onghena
IP: Patricia Pozo Rosich Collaborators: Alicia Alpuente Ruiz, Laila Asskour, Juli Alonso Farre, Eulalia Gine Cipres, Marta Torres Ferrús, Victor José Gallardo Lopez Funding agency: Instituto de Salud Carlos III Funding: 99999.97 Reference: AC19/00124 Duration: 01/01/2020 - 30/06/2024
IP: Alvaro Cobo Calvo Collaborators: Rosalia Horno Ocaña, Cristina Auger Acosta, Marta Rodríguez Barranco, Luciana Midaglia Fernandez, Breogan Rodriguez Acevedo, Mireia Castillo Juarez Funding agency: Instituto de Salud Carlos III Funding: 134915 Reference: PI20/00800 Duration: 01/01/2021 - 30/06/2025
IP: Carmen Tur Gomez Collaborators: Jordi Rio Izquierdo, Oscar Persiva Morenza, Elena Huerga Núñez Funding agency: Instituto de Salud Carlos III Funding: 150040 Reference: PI21/01860 Duration: 01/01/2022 - 31/12/2024
PMID: 37555258 Journal: Epidemiology and Psychiatric Sciences Year: 2023 Reference: Epidemiol Psychiatr Sci. 2023 Aug 9;32:e50. doi: 10.1017/S2045796023000628. Impact factor: Publication type: Paper in international publication Authors: Alayo, Itxaso; Alonso, Jordi; Amann, Benedikt L; Amigo, Franco; Aragon-Pena, Andres; Aragones, Enric; Asunsolo Del Barco, Angel; Bruffaerts, Ronny; Campos, Mireia; Del Cura-Gonzalez, Isabel et al. DOI: 10.1017/S2045796023000628
PMID: 37589724 Journal: ACTA NEUROCHIRURGICA Year: 2023 Reference: Acta Neurochir (Wien). 2023 Aug 17. doi: 10.1007/s00701-023-05739-8. Impact factor: Publication type: Paper in international publication Authors: Arikan, Fuat; Coscojuela, Pilar; De Barros, Andrea; Dinia, Lavinia; Gandara, Dario; Gramegna, Laura Ludovica; Hernandez, David; Luzi, Michele; Martinez-Saez, Elena; Quintana, Manuel et al. DOI: 10.1007/s00701-023-05739-8
PMID: 37580164 Journal: NEUROLOGY Year: 2023 Reference: Neurology. 2023 Aug 14:10.1212/WNL.0000000000207702. doi: 10.1212/WNL.0000000000207702. Impact factor: Publication type: Paper in international publication Authors: Auger, Cristina; Gonzalez, Victoria; Martinez-Saez, Elena; Naranjo, Laura; Ruiz-Garcia, Raquel; Vilaseca, Andreu et al. DOI: 10.1212/WNL.0000000000207702
PMID: 37658891 Journal: EUROPEAN RADIOLOGY Year: 2023 Reference: Eur Radiol. 2023 Sep 2. doi: 10.1007/s00330-023-10151-y. Impact factor: Publication type: Review in international publication Authors: Auger, Cristina; Auger, Cristina; Doniselli, Fabio M; Haider, Lukas; Hodel, Jerome; Jasperse, Bas; Mallio, Carlo A; Quattrocchi, Carlo C; Rovira, Alex; Rovira, Alex et al. DOI: 10.1007/s00330-023-10151-y
PMID: 35332015 Journal: AMERICAN JOURNAL OF NEURORADIOLOGY Year: 2022 Reference: AJNR Am J Neuroradiol. 2022 Apr;43(4):534-539. doi: 10.3174/ajnr.A7474. Epub 2022 Mar 24. Impact factor: 3.825 Publication type: Paper in international publication Authors: Caruana, G, Auger, C, Pessini, L M, Calderon, W, de Barros, A, Salerno, A, Sastre-Garriga, J, Montalban, X, Rovira, A et al. DOI: 10.3174/ajnr.A7474
PMID: 35202997 Journal: NeuroImage-Clinical Year: 2022 Reference: Neuroimage Clin. 2022;34:102967. doi: 10.1016/j.nicl.2022.102967. Epub 2022 Feb 16. Impact factor: 4.881 Publication type: Paper in international publication Authors: Boaventura, Mateus, Sastre-Garriga, Jaume, Garcia-Vidal, Aran, Vidal-Jordana, Angela, Quartana, Davide, Carvajal, Rene, Auger, Cristina, Alberich, Manel, Tintore, Mar, Rovira, Alex et al. DOI: 10.1016/j.nicl.2022.102967
PMID: 35048162 Journal: NEURORADIOLOGY Year: 2022 Reference: Neuroradiology. 2022 Jul;64(7):1383-1390. doi: 10.1007/s00234-021-02885-7. Epub 2022 Jan 20. Impact factor: 2.804 Publication type: Paper in international publication Authors: Pareto, Deborah, Garcia-Vidal, Aran, Groppa, Sergiu, Gonzalez-Escamilla, Gabriel, Rocca, Mara, Filippi, Massimo, Enzinger, Christian, Khalil, Michael, Llufriu, Sara, Sastre-Garriga, Jaume et al. DOI: 10.1007/s00234-021-02885-7
Els doctors Xavier Montalban, Àlex Rovira i Mar Tintoré han estat reconeguts en la categoria de Neurociències i Comportament, i el doctor Jordi Rello en la categoria Interdisciplinària.
The program, promoted by Biocat in collaboration with CIMIT (Boston), is aimed at entrepreneurs in the process of bringing their technology to market in the next few years.
